CEC ADVANTAGEA unique biomarker hiding in plain sight
Circulating Endothelial Cells (CEC)
It recently became clear that cells shed from sprouting cancer blood vessels into the main blood circulation in significant numbers[1,2].
Hailed as a “truly novel biomarker” for cancer, these so-called tumour-derived Circulating Endothelial Cells (CEC) are extremely difficult to detect because they are morphologically similar to healthy blood cells.
X-ZELL, however, found a way to isolate and characterize CEC at the single cell level, using our unique multi-marker detection technology.
CEC provide a wealth of information that current clinically approved liquid biopsies cannot deliver on. The result is a world-first approach that could revolutionise cancer cell detection as we know it.
Why are CEC so valuable?
- CEC shed from earliest stage cancers and could help us detect cancer early when it can be cured.
- CEC shed from smallest tumour sizes (1 mm), making them ultra-sensitive to the disease .
- CEC show the highest prevalence of all cell-based cancer markers, making them the ideal “point of attack” for cancer detection.
Why are CEC hard to find?
- CEC exhibit extensive antigen overlap with white blood cells, blood stem cells and healthy endothelial cells, making them extremely hard to differentiate.
- CEC cannot be isolated by targeting a single marker – they require the removal of healthy blood cells.
- The characterization of CEC requires advanced multiplexing of immunostaining, a technology exclusive to X-ZELL.
 Lin et al., Scientific Reports; 7(1):9789. (2017)
 Bhakdi et al. , Manuscript submitted (2017)
 Dudley. Cold Spring Harbor Perspectives in Medicine 2(3):1–18. (2012)
Get in Touch
Use the form below to contact us for more information.